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Abstract
Background: Febuxostat is a novel xanthine oxidase inhibitor. However, few studies have examined the long-term
efficacy and tolerability of febuxostat after switching from allopurinol in hemodialysis (HD) patients. Therefore, the
present study evaluated the long-term efficacy and tolerability of febuxostat in HD patients after switching from
allopurinol.
Findings: We monitored the levels of hemoglobin, hematocrit, platelet count, blood urea nitrogen, serum
creatinine, serum sodium, serum potassium, serum chloride, serum calcium, serum inorganic phosphorus,
aspartate transaminase, alanine aminotransferase, alkaline phosphatase, lactate dehydrogenase, and total protein that
were considered overall as a tolerability index, while the serum uric acid (UA) level was considered an index of efficacy.
All values were measured at baseline and at 1, 6, 12, and 16 months after the switch to febuxostat therapy. All subjects
switched from allopurinol (100 mg/day) to febuxostat (10 mg/day) in August 2013. Clinical laboratory data were
collected at baseline in July 2013 until December 2014. Nine patients were included in the study analysis. Results
showed that clinical laboratory data at baseline versus those at 16 months were not significantly different. Serum UA
levels, which represented the efficacy index, were significantly different between the baseline level (6.8 ± 1.4) and those
at 1, 6, 12, and 16 months (5.2 ± 1.1, 5.1 ± 1.1, 4.6 ± 0.9, and 5.4 ± 1.8 mg/dL, respectively; all p < 0.05).
Conclusion: Switching from allopurinol to febuxostat in HD patients reduced serum UA levels, with no changes in
other clinical laboratory data in the long term.
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Findings
Background
Hyperuricemia is known to be associated with hyperten-
sion, vascular disease, chronic kidney disease (CKD), and
cardiovascular disease (CVD) [1]. CVD is associated
with a risk of morbidity and mortality in hemodialysis
(HD) patients [2], and CKD patients receiving urate-
lowering therapy are mainly treated with xanthine oxi-
dase (XO) inhibitors [3].
Febuxostat is a novel XO inhibitor with urinary and
fecal pathways of excretion (49.1 and 44.9 %, respect-
ively) [4]. In a systematic review and meta-analysis study,
febuxostat did not reduce the risk of gout flares com-
pared with allopurinol, but the risk of adverse events
was lower in febuxostat compared with allopurinol, and
febuxostat was more likely than allopurinol to achieve
serum uric acid (UA) levels of <6 mg/dL [5]. In another
study, the incidence of adverse events was similar be-
tween allopurinol and febuxostat [6]. These studies sug-
gest that allopurinol is a safe option in non-CKD
patients. Oxypurinol, the major metabolite of allopur-
inol, is excreted via the kidney [7]. Some studies have
demonstrated an increased risk of allopurinol-induced ad-
verse reactions in CKD patients; however, the studies
evaluating allopurinol use in CKD patients have shown in-
consistent findings in relation to its safety and efficacy [8].
In HD patients, febuxostat therapy lowered serum UA
levels significantly after 6 months [8]. In CKD patients,
switching from allopurinol to febuxostat significantly de-
creased serum UA levels after 12 months [9]. However,
to date, few studies have examined the long-term effi-
cacy and tolerability of febuxostat when switching from
allopurinol in HD patients. Side effects of febuxostat
therapy for hyperuricemia in CKD patients have been
* Correspondence: ccrtyo34057@gmail.com
1Department of Pharmacy, Kaetsu Hospital, 1459-1 Higashikanazawa,
Akiha-ku, Niigata-shi, Niigata 956-0814, Japan
Full list of author information is available at the end of the article
© 2015 Mitsuboshi et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Mitsuboshi et al. Journal of Pharmaceutical Health Care and Sciences
 (2015) 1:28 
DOI 10.1186/s40780-015-0028-1
reported [9, 10], but few studies have examined the
pharmacokinetics of febuxostat in HD patients [11]. In
HD patients, we hypothesized that efficacy and toxicity
may be increased because serum concentrations of
febuxostat might be higher than those in non-HD pa-
tients. Therefore, in this study we evaluated the long-term
efficacy and tolerability of febuxostat in HD patients after
switching from allopurinol.
Methods
We conducted this 16-month prospective observational
study of HD patients who had been receiving allopurinol
at a dose of 100 mg/day for over 1 year. We excluded
patients who received allopurinol at a dose of 50 or
150 mg/day, because few patients had been receiving
allopurinol at these doses. We evaluated liver dysfunc-
tion in patients during the study period and also
excluded patients with a history of active liver disease.
All the enrolled patients switched from allopurinol at
100 mg/day to febuxostat at 10 mg/day in August 2013.
Clinical laboratory data were collected in the period
from July 2013 to December 2014. Blood samples were
obtained via vascular access before HD sessions. The
levels of hemoglobin, hematocrit, platelet count, blood
urea nitrogen, serum creatinine, serum sodium, serum po-
tassium, serum chloride, serum calcium, serum inorganic
phosphorus, aspartate transaminase, alanine aminotrans-
ferase, alkaline phosphatase, lactate dehydrogenase, and
total protein were assessed and were considered overall as
a tolerability index, while the serum UA level representing
the efficacy index was measured at baseline (July 2013)
and at 1, 6, 12, and 16 months after the switch to febuxo-
stat therapy (August 2013).
This study was performed in accordance with the Dec-
laration of Helsinki and was approved by the Ethics
Committee of Kaetsu Hospital. Written informed con-
sent was obtained from all patients before enrollment in
the study.
All data are expressed as mean ± standard deviation.
Statistical analysis was performed using the paired t-test,
and one-way ANOVA followed by Hsu’s MCB test. Signifi-
cance was set at p < 0.05. The software JMP 9 (SAS Insti-
tute Inc., Cary, NC) was used for all statistical analysis.
Result
Twelve HD patients receiving allopurinol were consid-
ered as candidate subjects. Three patients were excluded
from the study, including 2 who were receiving an allo-
purinol dose of 50 or 150 mg/day and 1 with a history of
active liver disease. Therefore, we assessed 9 patients in
this study. All 9 patients had oliguria or anuria, and
there was no change in diuretic therapy. They did not
receive any chronic steroid or non-steroidal anti-
inflammatory drugs during the study period.
Patient profiles are shown in Table 1, and patient med-
ications are shown in Table 2. Few changes to
hemodialysis prescriptions were made in this study. One
patient each had HD treatment time prolonged or short-
ened by 1 h, and the dialyzer membrane was changed
for 2 patients. In regards to anti-hypertensive agents,
angiotensin receptor blocker was added or withdrawn in
1 case each; calcium channel blocker was added in 1
case and withdrawn in 2; and alpha adrenergic blocker
was withdrawn in 1 patient. In regards to angiotensin
receptor blocker, patients had been administered azilsar-
tan, candesartan, or olmesartan. HMG-CoA reductase
inhibitor was added in 1 case. In regards to phosphate
binders, lanthanum carbonate or sevelamer hydrochlor-
ide was added in 1 case each, and lanthanum carbonate
was changed to sevelamer hydrochloride in 1 case. An
iron agent was added in 1 case, withdrawn in 1, added
and withdrawn in 6, and continued in 1 during the study
period. As for potassium-binding resin, 1 patient each
was administered calcium polystyrene sulfonate or
sodium polystyrene sulfonate. The dose of each of the
abovementioned medications was not changed during the
study period. Eight patients were administered erythropoi-
etin: the dose was increased in 4 patients, decreased in 1,
and increased and decreased in 2 during the study period.
All other medications were continued and their dosages
were not changed during the study period.
Changes in clinical laboratory data (which represent
the tolerability index) during the observation period are
shown in Table 3. The tolerability index showed no
Table 1 Patient profiles
N 9
Age (years) 62.3 ± 10.4
Sex (Female/Male) 1/8
Dry weight (kg) 59.7 ± 14.1
Hemodialysis duration (years) 12.4 ± 6.8
Etiology of renal disease (n)
Glomerulonephritis 4






Chronic heart failure 3
Diabetes 1
Unstable angina pectoris 1
Cerebral infarction 1
Values are means ± standard deviation
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statistical difference at baseline versus 16 months after
the switch to febuxostat therapy.
The effect of switching from allopurinol to febuxostat
on serum UA levels is shown in Fig. 1. The serum UA
level was significantly higher at baseline (6.8 ± 1.4) than at
1, 6, 12, and 16 months, respectively (5.2 ± 1.1, 5.1 ± 1.1,
4.6 ± 0.9, and 5.4 ± 1.8 mg/dL, respectively; all p < 0.05).
Serum UA levels < 6 mg/dL were noted in 3 patients
(33.3 %) at baseline and in 6 patients (66.7 %) at
16 months. Febuxostat dosage was reduced to 5 mg/day
from 10 mg/day at 12 months in 1 patient because serum
UA level before HD sessions had decreased to 4.4 mg/dL
from 5.7 mg/dL. Febuxostat dosage was not changed in
other patients during the study period. None of the
patients withdrew from this study because of side effects
or allergic reactions.
Discussion
Our study revealed that switching from allopurinol to
febuxostat in HD patients reduced serum UA levels,
with no changes in other clinical laboratory data. As
shown in Fig. 1, serum UA levels were 6.8 ± 1.4 and
5.4 ± 1.8 mg/dL at baseline and at 16 months after the
start of the study, respectively, with levels < 6 mg/dL noted
in 3 patients (33.3 %) and 6 patients (66.7 %) at these
times, respectively. In the previous study by Akimoto et al.
[8], febuxostat was shown to lower serum UA levels sig-
nificantly from 1 month to 6 months after initiation of the
treatment in HD patients, and serum UA levels < 6 mg/dL
were achieved in 82.3 % of patients after 6 months of
therapy. In the other study by Tsuruta et al. [9] in which
CKD (non-HD) patients switched from allopurinol to
Table 2 Patient medications
Medication Start of the study End of the study
Anti-hypertensive agents
Angiotensin receptor blocker 4, (4) 4, (4)
Calcium channel blocker 5, (4) 6, (4)
Alpha adrenergic blocker 2, (2) 1, (1)
Beta blockers 2, (2) 2, (2)
Loop diuretic 1, (1) 1, (1)
HMG-CoA reductase inhibitors 1, (1) 2, (2)
Phosphate binders
Calcium carbonate 7, (7) 7, (7)
Lanthanum carbonate 1, (1) 2, (2)
Sevelamer hydrochloride 5, (5) 6, (6)
number of medicine, (n)
Table 3 Changes in clinical laboratory data during the observation period
Follow-up period (months)
Baseline 6 12 16 p*
Hemoglobin (g/dL) 10.9 ± 0.8 10.7 ± 0.9 10.3 ± 0.8 10.4 ± 0.7 0.23
Hematocrit (%) 32.6 ± 2.2 32.5 ± 2.8 30.9 ± 1.9 31.7 ± 2.6 0.47
Platelet count (×104 cells/mm3) 13.6 ± 5.7 14.7 ± 6.4 14.1 ± 5.5 13.8 ± 5.4 0.71
Blood urea nitrogen (mg/dL) 65.9 ± 13.6 66.0 ± 11.3 57.5 ± 9.3 66.3 ± 12.3 0.94
Serum creatinine (mg/dL) 13.1 ± 2.5 12.8 ± 2.0 12.3 ± 1.9 12.4 ± 2.1 0.14
Serum sodium (mEq/L) 137.1 ± 1.8 138.1 ± 2.0 138.8 ± 1.4 138.2 ± 2.3 0.13
Serum potassium (mEq/L) 5.6 ± 0.5 5.2 ± 0.5 5.1 ± 0.5 5.7 ± 0.5 0.40
Serum chloride (mEq/L) 107.6 ± 2.1 106.8 ± 2.9 109.1 ± 2.2 108.4 ± 1.8 0.35
Serum calcium (mEq/L) 8.6 ± 0.3 8.5 ± 0.5 8.6 ± 0.4 8.6 ± 0.6 0.81
Serum inorganic phosphorus (mEq/L) 4.5 ± 0.6 4.9 ± 0.9 4.3 ± 0.8 5.0 ± 1.0 0.27
Aspartate transaminase (U/L) 10.2 ± 3.2 11.3 ± 4.4 9.2 ± 3.2 12.8 ± 5.4 0.21
Alanine aminotransferase (U/L) 10.4 ± 3.0 10.2 ± 3.3 9.8 ± 4.5 11.7 ± 4.7 0.54
Alkaline phosphatase (U/L) 196.6 ± 53.6 217.6 ± 82.6 198.0 ± 48.0 222.3 ± 67.1 0.09
Lactate dehydrogenase (U/L) 155.2 ± 27.1 157.6 ± 29.5 165.8 ± 23.3 165.3 ± 23.1 0.30
Total protein (g/dL) 5.9 ± 0.2 6.0 ± 0.4 5.9 ± 0.4 5.9 ± 0.3 0.63
Values are means ± standard deviation
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Fig. 1 The effect of switching from allopurinol to febuxostat on
serum UA levels
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febuxostat therapy, serum UA levels were 6.2 ± 0.9 mg/dL
and 5.7 ± 1.2 mg/dL at 3 months before and 12 months
after the switch, respectively; serum UA levels < 6 mg/dL
were achieved in 45.1 and 68.6 % of patients at these times
after the switch, respectively. Shoji et al. reported that
serum urate concentrations < 6 mg/dl reduced the fre-
quency of or prevented gout attacks [12]. The efficacy of
febuxostat in our study was similar; febuxostat therapy
may also reduce the risk of gout attacks in HD patients.
Moreover, this efficacy was maintained until 16 months
after the switch in therapy. In the present study, all pa-
tients began treatment with febuxostat at a dose of 10 mg/
day, switching from an allopurinol dose of 100 mg/day.
We considered the febuxostat dosage was an appropriate
starting dose given that the majority of the HD patients in
the study by Akimoto et al. [8] were treated with 10 mg of
febuxostat and their serum UA levels decreased signifi-
cantly from baseline values.
As shown in Table 3, clinical laboratory data (i.e.,
the tolerability index) showed no significant changes
during the period from baseline to 16 months after
the switch to febuxostat therapy. Similarly, in the
study by Akimoto et al. [8], clinical laboratory data
(representing the tolerability index) also showed no
significant changes from baseline to 6 months after
the start of the study. Febuxostat tolerability in our
study was therefore similar, but was continued over
16 months. We consider that febuxostat is a safer
therapy than allopurinol in CKD patients since some
studies have demonstrated they have an increased risk
of allopurinol-induced adverse reactions [3]. On the
other hand, febuxostat therapy for hyperuricemia in
CKD patients has been reported to cause acute neu-
tropenia [10] and liver dysfunction [9]; therefore, it is
important to monitor for these side effects in CKD
patients receiving febuxostat therapy.
Losartan, an angiotensin receptor blocker, has been
shown to increase urinary UA excretion and lower
serum UA levels [13], although this effect has not been
observed with other angiotensin receptor blockers. Pa-
tients were not administered losartan in the present
study. Sevelamer hydrochloride, which is a phosphate
binder, was found to be associated with a significant re-
duction in serum UA levels [14], and it was added or
withdrawn in 1 case each in the present study. There-
fore, we consider that angiotensin receptor blockers do
not affect serum UA levels but that sevelamer hydro-
chloride may affect them. Iron agents and erythropoietin
dosages were changed, but the levels of hemoglobin did
not differ significantly during the study period.
Blood pressure was not examined in this study; how-
ever, anti-hypertensive agents were added in 2 cases and
withdrawn in 4. Few studies have examined the effect of
febuxostat therapy on blood pressure in HD patients [8].
Based on our results, febuxostat therapy may have little
effect on blood pressure in HD patients.
Our study has certain limitations. These include the
small sample size, lack of a control group, and few
female patients. Also, urate-lowering therapy in HD pa-
tients has many potential confounders. In a previous
study, higher uric acid concentrations were associated
with a lower mortality among HD patients; higher uric
acid concentration is a known marker of better nutri-
tional status in this population [15]. Therefore, urate-
lowering therapy in HD patients should be the subject of
further investigation. In addition, the serum concentra-
tion of febuxostat in our HD patients was not assessed.
To date, few studies have examined the pharmacokinet-
ics of febuxostat in HD patients [11]. Febuxostat Tmax
and Cmax were not affected by CLcr; however, AUC24
was significantly associated with CLcr. In HD patients,
we consider that efficacy and toxicity may be increased
because serum concentrations of febuxostat may be
higher than those in non-HD patients. Therefore, when
febuxostat is administered to them, it is important to
consider that serum concentrations of febuxostat may be
higher than those in non-HD patients.
Overall, our results indicate that switching from
allopurinol to febuxostat in HD patients at a starting
dose of 10 mg/day can reduce serum UA levels, with
no changes in other clinical laboratory data over the
long term.
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